Issues affecting supply of palliative medicines into community pharmacy: A qualitative study of community pharmacist and pharmaceutical wholesaler/distributor perspectives
- PMID: 35909712
- PMCID: PMC9335932
- DOI: 10.1016/j.rcsop.2022.100132
Issues affecting supply of palliative medicines into community pharmacy: A qualitative study of community pharmacist and pharmaceutical wholesaler/distributor perspectives
Abstract
Background: Patient access to medicines in the community at end-of-life (pertaining to the last year of life) is vital for symptom control. Supply of such medicines is known to be problematic, but despite this, studies have failed to examine the issues affecting community pharmacy access to palliative medicines.
Objective: To identify community pharmacists' and pharmaceutical wholesalers'/distributors' views on supply chain processes and challenges in providing access to medicines during the last year of life, to characterise supply in this UK context.
Methods: Qualitative design, with telephone interviews analysed using Framework Analysis. Coding frames were developed iteratively with data analysed separately and then triangulated to examine differences in perspectives.
Findings: Thirty-two interviews (24 community pharmacists and 8 wholesalers/distributors) were conducted. To ensure appropriate palliative medicines were available despite occasional shortages, community pharmacists worked tirelessly. They navigated a challenging interface with wholesalers/distributors, the Drug Tariff to ensure reimbursement, and multiple systems. IT infrastructures and logistics provided by wholesalers/distributors were often helpful to supply into community pharmacies resulting in same or next day deliveries. However, the inability of manufacturers to predict operational issues or accurately forecast demand led wholesalers/distributors to encounter shortages with manufactured stock levels, reducing timely access to medicines.
Conclusions: The study identifies for the first time how palliative medicines supply into community pharmacy, can be improved. A conceptual model was developed, illustrating how influencing factors affect responsiveness and speed of medicines access for patients. Work is required to strengthen this supply chain via effective relationship-building and information-sharing, to prevent patients facing disruptions in access to palliative medicines at end-of-life.
Keywords: CD, Controlled Drug (controlled substances); CP, Community Pharmacist; Community pharmacy; End-of-life; EoL, End-of-Life (pertaining to the last year of life); FL, Full-line wholesaler; GP, General Practitioner (family doctor); I, Independent pharmacy; LM, Large multiple pharmacy; Medicines access; Palliative care medicines; Pharmaceutical wholesalers/distributors; SL, Short-line wholesaler; SM, Small multiple pharmacy; Supply; WD, Wholesaler/distributor.
© 2022 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Patient and carer access to medicines at end of life: the ActMed mixed-methods study.Southampton (UK): National Institute for Health and Care Research; 2022 Jul. Southampton (UK): National Institute for Health and Care Research; 2022 Jul. PMID: 35901229 Free Books & Documents. Review.
-
Access to palliative care medicines in the community: An evaluation of practice and costs using case studies of service models in England.Int J Nurs Stud. 2022 Aug;132:104275. doi: 10.1016/j.ijnurstu.2022.104275. Epub 2022 Apr 29. Int J Nurs Stud. 2022. PMID: 35667146
-
Stakeholder roles in facilitating access to essential medicines.Res Social Adm Pharm. 2019 Mar;15(3):260-266. doi: 10.1016/j.sapharm.2018.04.034. Epub 2018 May 4. Res Social Adm Pharm. 2019. PMID: 29752050
-
Pharmacists' views on the impact of the Falsified Medicines Directive on community pharmacies: A cross-sectional survey.Explor Res Clin Soc Pharm. 2022 Mar 20;5:100127. doi: 10.1016/j.rcsop.2022.100127. eCollection 2022 Mar. Explor Res Clin Soc Pharm. 2022. PMID: 35478525 Free PMC article.
-
The impact of global falsified medicines regulation on healthcare stakeholders in the legitimate pharmaceutical supply chain: a systematic review.Front Med (Lausanne). 2024 Jul 18;11:1429872. doi: 10.3389/fmed.2024.1429872. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39091292 Free PMC article.
Cited by
-
Factors Influencing Drug Shortages and Their Resolution in South Korean Community Pharmacies.Risk Manag Healthc Policy. 2024 Aug 30;17:2083-2095. doi: 10.2147/RMHP.S473859. eCollection 2024. Risk Manag Healthc Policy. 2024. PMID: 39228959 Free PMC article.
References
-
- Healthcare Distribution Alliance . 2020. Pharmaceutical distributors: understanding our role in the supply chain.https://www.hda.org/about/role-of-distributors Published 2020. Accessed 5th August 2020.
-
- Breen L. A preliminary examination of risk in the Pharmaceutical Supply Chain (PSC) in the National Health Service (NHS) J Serv Sci Manag. 2008;01(02):193–199.
-
- Breen L., Hou J., Sowter J. Advancing the understanding of pharmaceutical supply chain resilience using Complex Adaptive System (CAS) theory. Supply Chain Manag.: an Int. J. 2021;26(3):323–340.
-
- Narayana S.A., Pati R.K., Vrat P. Managerial research on the pharmaceutical supply chain–A critical review and some insights for future directions. J Purch Supply Manag. 2014;20(1):18–40.
-
- Rossetti C.L., Handfield R., Dooley K.J. Forces, trends, and decisions in pharmaceutical supply chain management. International Journal of Physical Distribution & Logistics Management. 2011;41(6):601–622.
LinkOut - more resources
Full Text Sources
Miscellaneous